Because of the reported high rate of coincidental infection with chlamydia, we give all patients with gonorrhoea (male and female) a 10-day course of oxytetracycline (500 mg twice daily). This course is the same as we use for non-specific urethritis (NSU) and contacts of non-specific urethritis, and is given after ampicillin 2 g and probenecid I g in one immediate oral dose. We have never regretted giving oxytetracycline in these cases. Such a regimen is associated with a low incidence of postgonococcal syndromes (3%), low treatment failure rates for gonorrhoea (<1070), and therefore less necessity for long-term follow up. One disadvantage may be that an increased number of women develop candidosis but this is usually diagnosed and treated before the final follow-up visit.
This management may not meet strictly academic ideas of "diagnosis before treatment," but in the absence of chlamydial cultures there seems no practical acceptable alternative (compare NSU and NSU contacts). Even if only a small percentage of men and women treated for gonorrhoea avoid chlamydial epididymitis or salpingitis by this means, it is surely worthwhile. In addition, it decreases the likelihood of partners reinfecting each other with chlamydia.
Yours faithfully, Michael J Balsdon S R S Laing G E Taylor 
